Provider review · Public documents checked September 27, 2026
Ivím tirzepatide records review: the product page is only one part
Separate the microdosing price table, membership agreement and medication-policy references before assuming they describe one complete promise.
Editorial source review, with no clinician sign-off or firsthand treatment experience claimed.
A reader might reasonably expect the price table to describe everything included in a medication program. Ivím's records show why that expectation needs checking. The microdosing page lists medicines and plan lengths; the membership agreement describes access; medication terms and refund policies add separate conditions. Each document has a role, and none should silently stand in for the others.
This review comes from Microdose Margin, a CoreAge Rx promotional-network publication with disclosed first commercial placement for CoreAge. It does not claim that relationship gives CoreAge better clinical care. We checked Ivím's public records on September 27, 2026, without purchasing a plan, testing support or examining any patient's medicine.
In this article
Documented: the tirzepatide row includes an added program charge
The microdosing page explicitly identifies compounded tirzepatide. It lists $133 per month for six months, $149 for four months and $200 for two months, with a separate $74.99 monthly program fee. The semaglutide column has different figures and should not be used as the tirzepatide price.
This establishes what the table advertises, without establishing a personal invoice or every charge under a selected agreement. The price-record guide explains why duration, medicine identity and payment structure belong with the headline. A monthly display is not, by itself, a full statement about commitment or medication supply.
Documented: membership is described as access, not a guaranteed prescription
The membership agreement describes ongoing care, professional visits and other services, with prescriptions when clinically appropriate. It specifically says the monthly access fee is not a purchase of a particular medicine or treatment. That qualification matters when someone interprets a paid membership as a promise of continued medication.
The May 2026 terms likewise condition prescribing on clinical judgment and describe an active-membership requirement for access. These are provider statements, not a legal determination about an individual dispute. They support asking which services and obligations belong to the selected program rather than relying on a general membership label.
Documented: refund language points to other sections
Ivím's refund policy describes prescription medicines as non-returnable and uses non-refundable language, but also refers cancellation eligibility to sections of its main terms. Section 16 discusses unshipped medication, administrative fees and a medically ineligible-continuation exception. Section 29 addresses program periods and lapse, with separate provisions for the GLP-1 ID program.
That chain of references is a reason to read the documents together. It would be incomplete to turn one isolated sentence into either a promise of a full refund or a universal statement that no exception exists. We did not cancel a plan, test a refund request or determine which provision controls a particular order.
Inferred: similarly named programs may not have identical terms
The main terms distinguish general medication programs from the specifically named GLP-1 ID program and explain how their sections relate. The public microdosing title alone does not settle every question about the individual agreement or its applicable provisions. A reviewer should not assign specialized rules merely because two names contain GLP-1.
A useful written clarification would identify the exact selected program and the relevant policy version. That is an administrative question, not permission to change a prescription. Program duration, remaining payment obligations and clinical continuation are separate matters, even when they appear within the same account or are discussed by the same support channel. Ask the service to identify the controlling documents in writing rather than treating a similar heading as confirmation of the same plan.
Inferred: a lower-amount description is not a safety finding
Ivím's product page markets a gentler approach while acknowledging that side effects and risks remain possible. Current Zepbound labeling provides context about substantial gastrointestinal, pancreatic, gallbladder and other risks, alongside its approved adult weight-management and sleep-apnea indications. It does not supply a measured safety rate for Ivím's compound.
FDA's GLP-1 information also describes errors and unapproved-product concerns. The adverse-event guide explains why reported events cannot be converted into an individual probability or used to certify another program as safer. A clinical discussion needs the actual medicine and health context, not the reassuring tone of a plan name.
Unresolved: the supplied preparation needs its own record
The public page identifies compounding, but an actual pharmacy record would be needed to establish the full preparation, dispensing source and accompanying instructions for an individual. FDA's FAQ explains that compounded medicines have not received finished-product approval. Descriptions of professional supervision do not change that distinction.
The compounding-record article separates these questions without providing quantities, measuring methods or substitution advice. Ivím advertises consultations and continuing check-ins; we have not observed them. Follow-up still needs to connect the intended benefit with unwanted effects and relevant changes in other medicines, health conditions or care.
Unresolved: what should the final explanation reconcile?
The remaining record should connect the named program, its charges and terms, the clinically proposed product and the team responsible for questions. If two pages seem inconsistent, an explanation tied to the actual selected arrangement is more useful than a review's guess. Neither a policy footnote nor a prescription establishes a demonstrated longevity benefit.
Our program comparison and CoreAge review apply the same document-reading standard. Ivím's current public offer is verified here; successful care, individual medication supply and a particular financial outcome are not. The distinction keeps the review useful without pretending to know what is outside its evidence.
Sources behind this reading
- Ivím Health: GLP-1 Microdosing ↗Provider product and price description · Checked 2026-09-27
- Ivím Health: Membership Agreement ↗Provider membership and payment terms · Checked 2026-09-27
- Ivím Health: Terms and Conditions, effective May 27, 2026 ↗Provider service terms; not an individual legal determination · Checked 2026-09-27
- Ivím Health: Return and Refund Policy ↗Provider policy and cross-referenced terms · Checked 2026-09-27
- Zepbound prescribing information, revised August 2026 ↗Current exact approved-product labeling · Checked 2026-09-27
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss ↗Regulatory safety communication · Checked 2026-09-27
- FDA: Compounding and the FDA, Questions and Answers ↗Regulatory product-status explanation · Checked 2026-09-27